Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Beta Bionics, Inc.BBNX · Entity 2350 | Chief Commercial Officer | October 01, 2026 | October 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Beta Bionics, Inc.
Report date October 01, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 56,109 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Sale · Disposed 370 · Balance 56,109 F1: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on June 10, 2026. F2: The weighted average sale price for the transaction reported was $18.96 and the range of prices were between $18.96 and $19.9599. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on June 10, 2026.
F2: The weighted average sale price for the transaction reported was $18.96 and the range of prices were between $18.96 and $19.9599. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 5, 2026 21:11 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 370 | $18.96 | $7,015.20 |
DisclosureSEC source: 0002048497-26-000018 · primarydocument.xml · nonDerivative · entry 1 Hopman Mark · CIK 0002048497 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,109 F1 · kind: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on June 10, 2026. F2 · price: The weighted average sale price for the transaction reported was $18.96 and the range of prices were between $18.96 and $19.9599. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| September 16, 2026 Filed Sep 17, 2026 20:15 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 30,779 | $20.13 | $619,639.75 |
DisclosureSEC source: 0002048497-26-000015 · form4-09172026_040905.xml · nonDerivative · entry 1 Hopman Mark · CIK 0002048497 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,479 F1 · kind: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on June 10, 2026. F2 · price: The weighted average sale price for the transaction reported was $20.1319 and the range of prices were between $20.00 and $20.64. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| September 14, 2026 Filed Sep 15, 2026 20:15 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 775 | $15.52 | $12,028.00 |
DisclosureSEC source: 0002048497-26-000014 · form4-09152026_040906.xml · nonDerivative · entry 1 Hopman Mark · CIK 0002048497 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,382 F1 · kind: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on June 10, 2026. Read SEC document |
| September 09, 2026 Filed Sep 18, 2026 23:51 UTC Amendment | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 35,994 | $18.46 | $664,550.02 |
DisclosureSEC source: 0002048497-26-000016 · form4a-09182026_110936.xml · nonDerivative · entry 1 Hopman Mark · CIK 0002048497 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 88,033 F1 · kind: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on June 10, 2026 (the "10b5-1 Plan"). F2 · shares: On September 10, 2026, the reporting person filed a Form 4 which incorrectly reported the number of shares disposed. The reporting person sold 35,994 shares under the 10b5-1 Plan on September 9, 2026 and the number of securities beneficially owned following the sale was 88,033 shares. F2 · balance_after: On September 10, 2026, the reporting person filed a Form 4 which incorrectly reported the number of shares disposed. The reporting person sold 35,994 shares under the 10b5-1 Plan on September 9, 2026 and the number of securities beneficially owned following the sale was 88,033 shares. Read SEC document |
| September 09, 2026 Filed Sep 10, 2026 20:30 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 36,870 | $18.46 | $680,723.44 |
DisclosureSEC source: 0002048497-26-000013 · form4-09102026_040903.xml · nonDerivative · entry 1 Hopman Mark · CIK 0002048497 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,157 F1 · kind: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on June 10, 2026. Read SEC document |
| September 02, 2026 Filed Sep 3, 2026 22:15 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 5,327 | $19.11 | $101,815.48 |
DisclosureSEC source: 0002048497-26-000012 · form4-09032026_060908.xml · nonDerivative · entry 1 Hopman Mark · CIK 0002048497 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,027 F1 · kind: The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units. F2 · price: The weighted average sale price for the transaction reported was $19.1131 and the range of prices were between $18.89 and $19.545. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| June 24, 2026 Filed Jun 25, 2026 20:34 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 1,258 | $15.01 | $18,880.44 |
DisclosureSEC source: 0002048497-26-000009 · form4-06252026_080606.xml · nonDerivative · entry 1 Hopman Mark · CIK 0002048497 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 129,354 F1 · kind: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 13, 2025. F2 · price: The weighted average sale price for the transaction reported was $15.0083 and the range of prices were between $15.00 and $15.015. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 22:05 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 275 | $12.31 | $3,385.25 |
DisclosureSEC source: 0002048497-26-000008 · form4-06052026_060603.xml · nonDerivative · entry 1 Hopman Mark · CIK 0002048497 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 130,612 F1 · kind: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 13, 2025. Read SEC document |
| June 02, 2026 Filed Jun 3, 2026 22:00 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 5,329 | $12.61 | $67,183.24 |
DisclosureSEC source: 0002048497-26-000007 · form4-06032026_060607.xml · nonDerivative · entry 1 Hopman Mark · CIK 0002048497 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,887 F1 · kind: The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units. F2 · price: The weighted average sale price for the transaction reported was $12.6071 and the range of prices were between $12.30 and $12.93. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 00:30 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 353 | $11.57 | $4,084.21 |
DisclosureSEC source: 0002048497-26-000002 · form4-03062026_120301.xml · nonDerivative · entry 1 Hopman Mark · CIK 0002048497 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 139,133 F1 · kind: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 13, 2025. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 23:45 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 834 | $12.36 | $10,309.57 |
DisclosureSEC source: 0002048497-26-000001 · form4-03032026_060310.xml · nonDerivative · entry 2 Hopman Mark · CIK 0002048497 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,486 F2 · kind: The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units. F3 · price: The weighted average sale price for the transaction reported was $12.3616 and the range of prices were between $12.20 and $12.55. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:45 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | GrantEmployee Stock Option (right to buy) · Derivative | 58,749 | $0.00 Strike: $12.63 | $0.00 |
DisclosureSEC source: 0002048497-26-000001 · form4-03032026_060310.xml · derivative · entry 3 Hopman Mark · CIK 0002048497 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,749 Underlying: Common Stock · 58,749 shares Expires 2036-02-26 F4 · derivative.exercise_date: The shares subject to this option shall vest in 36 equal monthly installments measured from March 1, 2026. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:45 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | GrantCommon Stock | 109,105 | $0.00 | $0.00 |
DisclosureSEC source: 0002048497-26-000001 · form4-03032026_060310.xml · nonDerivative · entry 1 Hopman Mark · CIK 0002048497 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,320 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan. Read SEC document |
| February 27, 2026 Filed Mar 13, 2026 20:15 UTC Amendment | Beta Bionics, Inc. BBNX · Entity 2350 | GrantEmployee Stock Option (right to buy) · Derivative | 91,520 | $0.00 Strike: $12.63 | $0.00 |
DisclosureSEC source: 0002048497-26-000003 · form4a-03132026_040307.xml · derivative · entry 1 Hopman Mark · CIK 0002048497 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,520 Underlying: Common Stock · 91,520 shares Expires 2036-02-26 F1 · derivative.exercise_date: The shares subject to this option shall vest in 36 equal monthly installments measured from March 1, 2026. Read SEC document |
| December 04, 2025 Filed Mar 16, 2026 23:55 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 2,061 | $30.66 | $63,192.32 |
DisclosureSEC source: 0002048497-26-000004 · form4-03162026_070303.xml · nonDerivative · entry 2 Hopman Mark · CIK 0002048497 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 136,216 F2 · kind: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 13, 2025. F3 · price: The weighted average sale price for the transaction reported was $30.6610 and the range of prices were between $30.02 and $31.0024. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 02, 2025 Filed Mar 16, 2026 23:55 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 856 | $29.34 | $25,111.53 |
DisclosureSEC source: 0002048497-26-000004 · form4-03162026_070303.xml · nonDerivative · entry 1 Hopman Mark · CIK 0002048497 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 138,277 F1 · kind: The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units. Read SEC document |
| September 05, 2025 Filed Sep 8, 2025 22:15 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 11,411 | $0.00 Strike: $5.10 | $0.00 |
DisclosureSEC source: 0001415889-25-023899 · form4-09082025_060903.xml · derivative · entry 8 Hopman Mark · CIK 0002048497 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,725 Underlying: Common Stock · 11,411 shares Expires 2033-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023. Read SEC document |
| September 05, 2025 Filed Sep 8, 2025 22:15 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 11,411 | $20.56 | $234,656.95 |
DisclosureSEC source: 0001415889-25-023899 · form4-09082025_060903.xml · nonDerivative · entry 5 Hopman Mark · CIK 0002048497 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,215 F1 · kind: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 13, 2025. F3 · price: The weighted average sale price for the transaction reported was $20.564162 and the range of prices were between $20.29 and $20.80. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| September 05, 2025 Filed Sep 8, 2025 22:15 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | Exercise / conversionCommon Stock | 11,411 | $5.10 | $58,196.10 |
DisclosureSEC source: 0001415889-25-023899 · form4-09082025_060903.xml · nonDerivative · entry 4 Hopman Mark · CIK 0002048497 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,626 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 22:15 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,093 | $0.00 Strike: $5.10 | $0.00 |
DisclosureSEC source: 0001415889-25-023899 · form4-09082025_060903.xml · derivative · entry 7 Hopman Mark · CIK 0002048497 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,136 Underlying: Common Stock · 4,093 shares Expires 2033-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 22:15 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 656 | $0.00 Strike: $5.10 | $0.00 |
DisclosureSEC source: 0001415889-25-023899 · form4-09082025_060903.xml · derivative · entry 6 Hopman Mark · CIK 0002048497 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,428 Underlying: Common Stock · 656 shares Expires 2033-07-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: One-fourth of the shares subject to this option shall vest one year after March 20, 2023, and thereafter 1/36th of the shares subject to this option shall vest on each monthly anniversary thereof. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 22:15 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 6,818 | $19.97 | $136,180.00 |
DisclosureSEC source: 0001415889-25-023899 · form4-09082025_060903.xml · nonDerivative · entry 3 Hopman Mark · CIK 0002048497 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,215 F1 · kind: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 13, 2025. F2 · price: The weighted average sale price for the transaction reported was $19.9736 and the range of prices were between $19.43 and $20.10. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 22:15 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | Exercise / conversionCommon Stock | 4,093 | $5.10 | $20,874.30 |
DisclosureSEC source: 0001415889-25-023899 · form4-09082025_060903.xml · nonDerivative · entry 2 Hopman Mark · CIK 0002048497 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,033 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 22:15 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | Exercise / conversionCommon Stock | 656 | $5.10 | $3,345.60 |
DisclosureSEC source: 0001415889-25-023899 · form4-09082025_060903.xml · nonDerivative · entry 1 Hopman Mark · CIK 0002048497 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,940 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 22:45 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 848 | $18.86 | $15,995.99 |
DisclosureSEC source: 0001415889-25-023743 · form4-09042025_060904.xml · nonDerivative · entry 1 Hopman Mark · CIK 0002048497 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,284 F1 · kind: The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units. F2 · price: The weighted average sale price for the transaction reported was $18.8632 and the range of prices were between $18.58 and $19.09. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| August 19, 2025 Filed Aug 21, 2025 01:30 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 16,158 | $0.00 Strike: $5.10 | $0.00 |
DisclosureSEC source: 0001415889-25-022540 · form4-08202025_090803.xml · derivative · entry 3 Hopman Mark · CIK 0002048497 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,084 Underlying: Common Stock · 16,158 shares Expires 2033-07-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: One-fourth of the shares subject to this option shall vest one year after March 20, 2023, and thereafter 1/36th of the shares subject to this option shall vest on each monthly anniversary thereof. Read SEC document |
| August 19, 2025 Filed Aug 21, 2025 01:30 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 16,158 | $16.61 | $268,376.30 |
DisclosureSEC source: 0001415889-25-022540 · form4-08202025_090803.xml · nonDerivative · entry 2 Hopman Mark · CIK 0002048497 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,132 F1 · kind: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 13, 2025. F2 · price: The weighted average sale price for the transaction reported was $16.6095 and the range of prices were between $16.26 and $17.1719. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| August 19, 2025 Filed Aug 21, 2025 01:30 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | Exercise / conversionCommon Stock | 16,158 | $5.10 | $82,405.80 |
DisclosureSEC source: 0001415889-25-022540 · form4-08202025_090803.xml · nonDerivative · entry 1 Hopman Mark · CIK 0002048497 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,290 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 23:30 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 79 | $18.69 | $1,476.59 |
DisclosureSEC source: 0001415889-25-015670 · form4-06042025_070616.xml · nonDerivative · entry 3 Hopman Mark · CIK 0002048497 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,132 F1 · kind: The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units. F4 · price: The weighted average sale price for the transaction reported was $18.691 and the range of prices were between $18.69 and $18.73. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 23:30 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 551 | $18.15 | $10,000.04 |
DisclosureSEC source: 0001415889-25-015670 · form4-06042025_070616.xml · nonDerivative · entry 2 Hopman Mark · CIK 0002048497 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,211 F1 · kind: The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units. F3 · price: The weighted average sale price for the transaction reported was $18.1489 and the range of prices were between $17.62 and $18.60. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 23:30 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 238 | $17.03 | $4,052.66 |
DisclosureSEC source: 0001415889-25-015670 · form4-06042025_070616.xml · nonDerivative · entry 1 Hopman Mark · CIK 0002048497 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,762 F1 · kind: The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units. F2 · price: The weighted average sale price for the transaction reported was $17.028 and the range of prices were between $16.62 and $17.56. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| February 27, 2025 Filed Mar 3, 2025 22:45 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | GrantEmployee Stock Option (right to buy) · Derivative | 52,000 | $0.00 Strike: $19.91 | $0.00 |
DisclosureSEC source: 0001415889-25-006234 · form4-03032025_050311.xml · derivative · entry 2 Hopman Mark · CIK 0002048497 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,000 Underlying: Common Stock · 52,000 shares Expires 2035-02-26 F2 · derivative.exercise_date: The shares subject to this option shall vest in 36 equal monthly installments measured from February 27, 2025. Read SEC document |
| February 27, 2025 Filed Mar 3, 2025 22:45 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | GrantCommon Stock | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006234 · form4-03032025_050311.xml · nonDerivative · entry 1 Hopman Mark · CIK 0002048497 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 01:30 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | GrantEmployee Stock Option (right to buy) · Derivative | 47,775 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001415889-25-002817 · form4-02032025_080206.xml · derivative · entry 5 Hopman Mark · CIK 0002048497 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,775 Underlying: Common Stock · 47,775 shares Expires 2035-01-28 F6 · derivative.exercise_date: Vesting is monthly over a 48-month period starting January 29, 2025 in equal monthly amounts. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 01:30 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | GrantEmployee Stock Option (right to buy) · Derivative | 39,424 | $0.00 Strike: $10.74 | $0.00 |
DisclosureSEC source: 0001415889-25-002817 · form4-02032025_080206.xml · derivative · entry 4 Hopman Mark · CIK 0002048497 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,424 Underlying: Common Stock · 39,424 shares Expires 2034-09-29 F5 · derivative.exercise_date: The shares subject to this option shall vest in 48 equal monthly installments measured from September 30, 2024. F2 · derivative.underlying: Immediately prior to the closing of the initial public offering, each share of Class B Common Stock subject to this option was converted into an equal number of shares of Common Stock. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 01:30 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | GrantEmployee Stock Option (right to buy) · Derivative | 17,765 | $0.00 Strike: $8.51 | $0.00 |
DisclosureSEC source: 0001415889-25-002817 · form4-02032025_080206.xml · derivative · entry 3 Hopman Mark · CIK 0002048497 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,765 Underlying: Common Stock · 17,765 shares Expires 2033-12-31 F4 · derivative.exercise_date: The shares subject to this option shall vest in 48 equal monthly installments measured from January 1, 2024. F2 · derivative.underlying: Immediately prior to the closing of the initial public offering, each share of Class B Common Stock subject to this option was converted into an equal number of shares of Common Stock. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 01:30 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | GrantEmployee Stock Option (right to buy) · Derivative | 37,229 | $0.00 Strike: $5.10 | $0.00 |
DisclosureSEC source: 0001415889-25-002817 · form4-02032025_080206.xml · derivative · entry 2 Hopman Mark · CIK 0002048497 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,229 Underlying: Common Stock · 37,229 shares Expires 2033-09-13 F3 · derivative.exercise_date: The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023. F2 · derivative.underlying: Immediately prior to the closing of the initial public offering, each share of Class B Common Stock subject to this option was converted into an equal number of shares of Common Stock. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 01:30 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | GrantEmployee Stock Option (right to buy) · Derivative | 83,242 | $0.00 Strike: $5.10 | $0.00 |
DisclosureSEC source: 0001415889-25-002817 · form4-02032025_080206.xml · derivative · entry 1 Hopman Mark · CIK 0002048497 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,242 Underlying: Common Stock · 83,242 shares Expires 2033-07-26 F1 · derivative.exercise_date: One-fourth of the shares subject to this option shall vest one year after March 20, 2023, and thereafter 1/36th of the shares subject to this option shall vest on each monthly anniversary thereof. F2 · derivative.underlying: Immediately prior to the closing of the initial public offering, each share of Class B Common Stock subject to this option was converted into an equal number of shares of Common Stock. Read SEC document |
| January 29, 2025 Filed Jan 31, 2025 21:31 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | GrantEmployee Stock Option (right to buy) · Derivative | 47,775 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001415889-25-002480 · form4-01312025_090153.xml · derivative · entry 1 Hopman Mark · CIK 0002048497 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,775 Underlying: Class B Common Stock · 47,775 shares Expires 2035-01-28 F1 · derivative.exercise_date: Vesting is monthly over a 48-month period starting January 29, 2025 in equal monthly amounts. F2 · derivative.underlying: Immediately prior to the closing of the initial public offering, each share of Class B Common Stock subject to this option was converted into an equal number of shares of Common Stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.